Tengyi Zhang

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Lei Zheng · 5 shared papers, 2022–2025 · strength 0.83
   • Paper Comparison of Shared Class I HLA-Bound Noncanonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Ade… DOI 10.1158/1078-0432.ccr-24-2251↗
   • Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
2. Robert A. Anders · 3 shared papers, 2022–2024 · strength 0.39
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
   • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
3. Jin Peng He · 3 shared papers, 2022–2024 · strength 0.39
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
   • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
4. Keyu Li · 3 shared papers, 2022–2024 · strength 0.39
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
   • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
5. Elizabeth M. Jaffee · 3 shared papers, 2022–2024 · strength 0.39
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
   • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
6. Amol Kumar Narang · 3 shared papers, 2022–2024 · strength 0.39
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
   • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
7. Daniel A. Laheru · 3 shared papers, 2022–2024 · strength 0.39
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
   • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
   • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
8. Kenji Fujiwara · 2 shared papers, 2022–2023 · strength 0.32
   • Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
   • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
9. Nan Niu · 2 shared papers, 2022–2024 · strength 0.31
   • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
   • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
10. Tao Xia · 2 shared papers, 2022–2024 · strength 0.26
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
    • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
11. Arsen Osipov · 2 shared papers, 2022–2024 · strength 0.26
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
    • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
12. Hao Wang · 2 shared papers, 2022–2023 · strength 0.23
    • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
    • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
13. Thatcher Ross Heumann · 2 shared papers, 2022–2023 · strength 0.23
    • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
    • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
14. Christopher L. Wolfgang · 2 shared papers, 2022–2023 · strength 0.23
    • Paper A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD1… DOI 10.1038/s41467-023-39196-9↗
    • Paper Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatme… DOI 10.1016/j.ccell.2022.10.001↗
15. Sophia Y. Chen · 1 shared paper, 2023 · strength 0.17
    • Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
16. Jianxin Wang · 1 shared paper, 2023 · strength 0.17
    • Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
17. Heng‐Chung Kung · 1 shared paper, 2023 · strength 0.17
    • Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
18. Jun Yu · 1 shared paper, 2023 · strength 0.17
    • Paper Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. DOI 10.1016/j.canlet.2023.216366↗
19. Brian T. Herbst · 1 shared paper, 2022 · strength 0.16
    • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
20. Stephen T. Muth · 1 shared paper, 2022 · strength 0.16
    • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
21. Lei Zheng · 1 shared paper, 2022 · strength 0.16
    • Paper Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spect… DOI 10.1186/s13045-022-01373-6↗
22. Jun-Ke Wang · 1 shared paper, 2024 · strength 0.16
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
23. Valerie Lee · 1 shared paper, 2024 · strength 0.16
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
24. Joseph M. Herman · 1 shared paper, 2024 · strength 0.16
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗
25. Hao Wang · 1 shared paper, 2024 · strength 0.16
    • Paper Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances … DOI 10.1126/sciadv.adk1827↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.